Healthcare -
Biotechnology - NYSE - US
$ 7.61
-9.17 %
$ 806 M
Market Cap
-2.59
P/E
INCOME STATEMENT
EFFICIENCY
Earnings Waterfall
Arcus Biosciences, Inc.
| Revenue | 258 M |
| Cost Of Revenue | 10 M |
| Gross Profit | 248 M |
| Operating Expenses | 588 M |
| Operating Income | -330 M |
| Other Expenses | -47 M |
| Net Income | -283 M |
Income Statement
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | |
|---|---|---|---|---|---|---|---|---|---|
| REVENUE | |||||||||
| Revenue | 258.0 | 117.0 | 112.0 | 382.9 | 77.5 | 15.0 | 8.4 | 1.4 | 0 |
| GROSS PROFIT | |||||||||
| Cost Of Revenue | 10.0 | 340.0 | 14.0 | 7.1 | 159.0 | 78.5 | 49.6 | 2.6 | 1.3 |
| Gross Profit | 248.0 | (223.0) | 98.0 | 375.8 | (81.5) | (63.5) | (41.3) | (1.2) | (1.3) |
| OPERATING INCOME | |||||||||
| Operating Expenses | 588.0 | 457.0 | 392.0 | 328.6 | 201.8 | 103.7 | 63.2 | 54.9 | 18.2 |
| Selling, General and Administrative Expenses | 120.0 | 117.0 | 104.0 | 72.3 | 42.4 | 25.2 | 13.6 | 7.6 | 3.9 |
| Research and Development Expenses | 448.0 | 340.0 | 288.0 | 256.3 | 159.3 | 78.5 | 49.6 | 47.2 | 14.2 |
| Operating Income | (330.0) | (340.0) | (280.0) | 54.2 | (124.2) | (88.7) | (54.9) | (53.4) | (18.2) |
| PRE-TAX INCOME | |||||||||
| Interest Income Expense | 4.0 | 2.0 | 2.0 | 0.3 | 0 | 0 | 4.9 | 0 | 0 |
| Total Other Income | 47.0 | 39.0 | 14.0 | 0.4 | 1.4 | 4.0 | 5.3 | 0.4 | 0.2 |
| Pre-Tax Income | (283.0) | (301.0) | (266.0) | 54.6 | (122.9) | (84.7) | (49.6) | (53.1) | (18.0) |
| NET INCOME | |||||||||
| Tax Provision | 1.0 | 6.0 | 1.0 | 1.8 | (6.2) | (8.8) | 5.3 | 0 | 0 |
| Net Income | (283.0) | (307.0) | (267.0) | 53.0 | (116.7) | (75.9) | (49.6) | (53.1) | (18.0) |
| EPS | 3.14 | 4.15 | 3.71 | 0.76 | 2.13 | 1.73 | 1.43 | 1.25 | 0.73 |